AR033459A1 - Uso de (41-trifluorometilfenil)-amida del acido (z)-2-ciano-3-hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple - Google Patents

Uso de (41-trifluorometilfenil)-amida del acido (z)-2-ciano-3-hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple

Info

Publication number
AR033459A1
AR033459A1 ARP020101245A ARP020101245A AR033459A1 AR 033459 A1 AR033459 A1 AR 033459A1 AR P020101245 A ARP020101245 A AR P020101245A AR P020101245 A ARP020101245 A AR P020101245A AR 033459 A1 AR033459 A1 AR 033459A1
Authority
AR
Argentina
Prior art keywords
treatment
multiple sclerosis
trifluorometilfenil
hydroxi
enoic
Prior art date
Application number
ARP020101245A
Other languages
English (en)
Spanish (es)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26246599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR033459(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0123571.2A external-priority patent/GB0123571D0/en
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of AR033459A1 publication Critical patent/AR033459A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP020101245A 2001-04-05 2002-04-04 Uso de (41-trifluorometilfenil)-amida del acido (z)-2-ciano-3-hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple AR033459A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28168501P 2001-04-05 2001-04-05
GBGB0123571.2A GB0123571D0 (en) 2001-04-05 2001-10-02 Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
AR033459A1 true AR033459A1 (es) 2003-12-17

Family

ID=26246599

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101245A AR033459A1 (es) 2001-04-05 2002-04-04 Uso de (41-trifluorometilfenil)-amida del acido (z)-2-ciano-3-hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple

Country Status (15)

Country Link
EP (2) EP1935416A3 (enExample)
AR (1) AR033459A1 (enExample)
AT (1) ATE396719T1 (enExample)
CA (1) CA2443285C (enExample)
CY (1) CY2014004I2 (enExample)
DE (1) DE60226855D1 (enExample)
DK (1) DK1381356T3 (enExample)
ES (1) ES2305287T3 (enExample)
FR (1) FR14C0010I2 (enExample)
LU (1) LU92366I2 (enExample)
PA (1) PA8542901A1 (enExample)
PT (1) PT1381356E (enExample)
SI (1) SI1381356T1 (enExample)
UY (1) UY27244A1 (enExample)
WO (1) WO2002080897A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7323443B2 (en) 2002-12-12 2008-01-29 Agennix Inc. Lactoferrin in the reduction of pain
MX2007004265A (es) * 2004-10-19 2008-03-04 Aventis Pharma Inc Uso de (4'trifluorometilfenil) -amida del acido (z) - 2 - ciano - 3 - hidroxi-but - 2- enoico para tratar la enfermedad inflamatoria del intestino.
JP5021488B2 (ja) 2004-12-21 2012-09-05 メルク セローノ ソシエテ アノニム スルホニルアミノ環式誘導体及びその使用
ZA200705623B (en) 2005-01-31 2008-09-25 Serono Lab N-hydroxyamide derivatives and use thereof
BRPI0616118A2 (pt) 2005-09-01 2011-06-07 Ares Trading Sa tratamento de neurite ótica
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
EP2100881A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Pyrimidyl- or pyridinylaminobenzoic acid derivatives
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2277515A1 (en) * 2009-07-10 2011-01-26 Sanofi-Aventis Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
CR20170078A (es) * 2009-09-18 2017-05-22 Sanofi Sa Formulaciones en compromido de la (4-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibutil-2-enoico con estabilidad mejorada
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
WO2012109329A2 (en) 2011-02-08 2012-08-16 Children's Medical Center Corporation Methods for treatment of melanoma
EP2762135A1 (en) * 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
WO2016189406A1 (en) 2015-05-23 2016-12-01 Ftf Pharma Private Limited Pharmaceutical composition of teriflunomide
JOP20190207A1 (ar) 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على بونيسيمود
GR1010137B (el) 2020-12-15 2021-12-07 Φαρματεν Α.Β.Ε.Ε., Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL178596C (nl) 1975-06-05 1986-04-16 Hoechst Ag Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden.
DE2854439A1 (de) 1978-12-16 1980-07-03 Hoechst Ag Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
DE3534440A1 (de) 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
TW314467B (enExample) 1993-03-31 1997-09-01 Hoechst Ag
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
DE19547648A1 (de) * 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate

Also Published As

Publication number Publication date
EP1381356B1 (en) 2008-05-28
EP1935416A2 (en) 2008-06-25
CA2443285A1 (en) 2002-10-17
CY2014004I1 (el) 2015-12-09
DE60226855D1 (de) 2008-07-10
CA2443285C (en) 2007-08-21
UY27244A1 (es) 2002-07-31
EP1935416A3 (en) 2008-10-22
WO2002080897A1 (en) 2002-10-17
PT1381356E (pt) 2008-07-24
CY2014004I2 (el) 2015-12-09
ATE396719T1 (de) 2008-06-15
SI1381356T1 (sl) 2008-12-31
LU92366I2 (fr) 2014-03-31
FR14C0010I1 (enExample) 2014-03-14
EP1381356A1 (en) 2004-01-21
DK1381356T3 (da) 2008-09-22
ES2305287T3 (es) 2008-11-01
FR14C0010I2 (fr) 2014-11-21
PA8542901A1 (es) 2003-11-12

Similar Documents

Publication Publication Date Title
AR033459A1 (es) Uso de (41-trifluorometilfenil)-amida del acido (z)-2-ciano-3-hidroxi-but-2-enoico para el tratamiento de la esclerosis multiple
UY28014A1 (es) Compuestos quimicos
ECSP024244A (es) Uso de (z)-2-cyano-3-hydroxy-but-2-enoic acid(4´-trifluoromethylphenyl)-amide para el tratamiento de la esclerosis múltiple
ECSP055851A (es) Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
CY1111481T1 (el) Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης
AR051778A2 (es) Derivados del acido dimetilaminocrotonico y procesos para supreparacion
GT200100196A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7.
TW200616940A (en) Novel hexafluoroisopropanol substituted ether derivatives
MX2010003224A (es) Derivados de biaril sulfonamida.
DOP2005000006A (es) "derivados de sulfonamida para el tratamiento de enfermedades"
ATE427932T1 (de) 11beta-hsd1-inhibitoren
SE0200979D0 (sv) New compounds
PE20020220A1 (es) Compuestos de nitrilo de dipeptido como inhibidores de catepsina k
SE0100172D0 (sv) New inhibitors against galectins
GB0127903D0 (en) Improvements relating to organic compounds
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
SE0301888D0 (sv) New use VII
SE0301882D0 (sv) New use I
SE0100569D0 (sv) New compounds
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
BR0306922A (pt) N-pirazinil-fenilsulfonamidas e seu uso no tratamento de doenças mediadas por quimocina
BR0314212A (pt) Projeto de análogos de quimiocina para o tratamento de doenças humanas
DE60322103D1 (de) Pharmazeutische zusammensetzungen mit sertaconazol für vaginale verwendung
BR0305708A (pt) Derivados de benzimidazol para o tratamento de disfunção sexual
BR0205812A (pt) Benzimidazois úteis no tratamento da disfunção sexual

Legal Events

Date Code Title Description
FA Abandonment or withdrawal